If the clinical efficacy of these two drugs is associated with their ability to target the CD44+ PCa cells and if CSCs, as hypothesized, represent the cells at the root of tumor maintenance, progression, recurrence, and metastasis, why cannot etoposide and paclitaxel completely ablate the tumors and cure the patients? This evidence concerns the gene CD44 and neoplasm.